moxonidine has been researched along with Dementia in 1 studies
moxonidine: structure given in first source
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martynov, AI | 1 |
| Ostroumova, OD | 1 |
| Korsakova, NK | 1 |
| Sergienko, VB | 1 |
| Varako, NA | 1 |
| Bagramova, IuA | 1 |
1 trial available for moxonidine and Dementia
| Article | Year |
|---|---|
[Influence of long-term moxonidine (psysiotens) monotherapy on neuropsychological status and brain perfusion in elderly patients with arterial hypertension].
Topics: Aged; Antihypertensive Agents; Brain; Cognition; Dementia; Female; Frontal Lobe; Humans; Hypertensio | 2002 |